Attached files

file filename
EX-31.1 - EXHIBIT 31.1 - DR. TATTOFF, INC.ex31-1.htm
EX-31.2 - EXHIBIT 31.2 - DR. TATTOFF, INC.ex31-2.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K/A
Amendment No. 2
 

x  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
 
ACT OF 1934
 
 For the fiscal year ended December 31, 2011
 
OR
 
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
 
EXCHANGE ACT OF 1934
 
For the transition period from
 
to
 
 
Commission file number:  000-52836
 
Dr. Tattoff, Inc.
(Exact name of registrant as specified in its charter)
 
Florida
20-0594204
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
 
8500 Wilshire Boulevard, Suite 105
Beverly Hills, California, 90211
(Address of principal executive offices)
 
(310) 659-5101
(Registrant’s telephone number,
including area code)

 Securities registered pursuant to Section 12(b) of the Act:
 
Title of Class
  Name of each exchange on which registered
   None  
  None
       
  Securities registered pursuant to Section 12(g) of the Act:
 
 
  Common Stock, $.0001 par value
(Title of class)
 
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.        Yes   o   No    x
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes   o   No    x
 
 Note: Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from their obligation under those Sections.
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes o No x
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulations S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes  x No o

Indicate by check mark if disclosure of delinquent filers pursuant to Rule 405 of Regulation S-K (229.405 of this chapter) is not contained herein and will not be contained, to the best of
registrants knowledge, in definitive proxy or other information incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K o
 
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer o
Accelerated filer o
 
     
Non-accelerated filer o
Smaller reporting company x
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
 
As there is no market for our common stock as of June 30, 2011, the aggregate market value of the common stock held by non-affiliates (11,261,796 shares) cannot be determined.
  
The number of shares of the registrant’s common stock, $0.0001 par value, outstanding as of March 21, 2012 was 14,727,227 shares.
 
DOCUMENTS INCORPORATED BY REFERENCE
 
None.
 
 
 

 
   
EXPLANATORY NOTE

Dr. Tattoff, Inc. is filing this Amendment No. 2 (“Amendment No. 2”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2011, which was originally filed with the Securities and Exchange Commission on March 29, 2012 (the “Annual Report”), as amended by Amendment No. 1 to the Annual Report, as filed on April 25, 2012 (“Amendment No. 1”), to file Exhibits 31.1 and 31.2 to Amendment No. 1 to the Annual Report. There are no changes to the disclosures in the Annual Report, including the financial statements filed therein.  There are no changes to the disclosures in Amendment No. 1, except that this Amendment No. 2 files Exhibits 31.1 and 31.2 that were omitted from Amendment No. 1.
 
 
 

 
 
Item 15. Exhibits, Financial Statement Schedules
 
(a)           Exhibits:
 
 
 The following exhibits have been filed as a part of this Amendment No. 2.
 
 
Exhibit
Number
 
Description
31.1
 
Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2
 
Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 

 

SIGNATURES

Pursuant to the requirements of Sections 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  DR. TATTOFF, INC.  
     
       
 
By:
/s/ John P. Keefe  
    John P. Keefe  
    Chief Executive Officer  
       
       
Date: May 22, 2012